Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Pankaj ShahDesignation :- Managing Director / Whole Time Director Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Company Secretary & Compliance Officer. Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Result For The Quarter Ended December 31, 2021
Financial Result for the quarter ended December 31, 2021 Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of The Board Meeting Held On February 12, 2022
Outcome of the Board Meeting held on February 12, 2022 Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Company For The Quarter Ended December 31, 2021.
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 ,inter alia, to consider and approve the un-audited financial results of the Company for the quarter ended December 31, 2021. Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholding for the Period Ended December 31, 2021
Aspira Pathlab & Diagnostics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, for the quarter ended December 31, 2021. Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Darshana SawantDesignation :- Company Secretary and Compliance Officer Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the code of Prohibition of Insider Trading adopted by Company, the trading window for dealing in securities of the company will remain closed from January 01, 2022, till 48 hours after declaration of Un-audited Financial Results of the Company for the Quarter ended December 31, 2021. Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 For The Half Year Ended September 30, 2021.
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure on Related Party Transactions, on standalone basis, drawn in accordance with applicable accounting standards for the half-year ended September 30, 2021.